Literature DB >> 31173655

Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis.

Amani Beshara1,2, Maya Ahoroni1, Doron Comanester2, Alex Vilkin1, Doron Boltin1,2, Iris Dotan1,2, Yaron Niv1,2, Arnon D Cohen3,4, Zohar Levi1,2.   

Abstract

We evaluated time to colonoscopy after a positive guaiac-based fecal occult blood test (gFOBT) result and its association with the risk of overall colorectal cancer (CRC) and advanced-stage disease at diagnosis. We conducted a retrospective cohort study (2011-2013) within the Clalit Health Services, Israel. Participants were patients between 50 and 74 years old with a positive gFOBT result who had follow-up colonoscopies within 24 months. The exposure was time to colonoscopy, and the main outcome measure was a risk for overall and advanced CRC (defined as Stages III-IV). Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for patient demographics and baseline risk factors. Of the 17,958 patients with positive gFOBT results (median age, 61 years [interquartile range, 56-67 years]; women, 52.2%), there were 685 cases of CRC and 156 cases of an advanced-stage disease diagnosed. The rate of cancer diagnosis at 0-3, 4-6, 7-9, 10-12 and 13-24 months was 3.9%, 2.5%, 3.5%, 4.2% and 7.3%, respectively (p < 0.001). Compared to colonoscopy follow-up within 0-3 months, risks for any CRC and advanced stage disease were higher for a follow-up of 12-24 months: OR, 1.97 (95% CI, 1.51-2.56) and 1.88 (95% CI, 1.43-2.46), respectively. For right-sided cancer (n = 194), an increased risk starts at 10 months, OR, 1.91 (95% CI 1.03-3.56). A result of 3-6 positive fields was significantly associated diagnosis of cancer (OR, 5.52; 95% CI, 4.71-6.46) and advanced stage disease (OR, 8.07; 95% CI, 5.74-11.36). Encouraging an early uptake of colonoscopy and targeting those with 10-24 months delay and a 3-6 positive fields is warranted.
© 2019 UICC.

Entities:  

Keywords:  positive fecal occult blood test; risk of colorectal cancer; time to colonoscopy

Mesh:

Substances:

Year:  2019        PMID: 31173655     DOI: 10.1002/ijc.32497

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Patient Navigation After Positive Fecal Immunochemical Test Results Increases Diagnostic Colonoscopy and Highlights Multilevel Barriers to Follow-Up.

Authors:  Vivy T Cusumano; Anthony Myint; Edgar Corona; Liu Yang; Jennifer Bocek; Antonio G Lopez; Marcela Zhou Huang; Naveen Raja; Anna Dermenchyan; Lily Roh; Maria Han; Daniel Croymans; Folasade P May
Journal:  Dig Dis Sci       Date:  2021-02-20       Impact factor: 3.199

2.  Exosomal circ_PTPRA inhibits tumorigenesis and promotes radiosensitivity in colorectal cancer by enriching the level of SMAD4 via competitively binding to miR-671-5p.

Authors:  Ying Yang; Nengwen Yang; Jun Jiang
Journal:  Cytotechnology       Date:  2022-01-11       Impact factor: 2.058

3.  Evaluation of a multimedia outreach campaign for a multi-target stool DNA test for colorectal cancer screening among non-medicare employer population in the United States.

Authors:  Martha E Shepherd; Ashlee Lecorps; Lori Inman; Lesley-Ann Miller-Wilson
Journal:  Prev Med Rep       Date:  2022-05-31

4.  Time to Colonoscopy After Abnormal Stool-Based Screening and Risk for Colorectal Cancer Incidence and Mortality.

Authors:  Yazmin San Miguel; Joshua Demb; Maria Elena Martinez; Samir Gupta; Folasade P May
Journal:  Gastroenterology       Date:  2021-02-02       Impact factor: 22.682

5.  Preferences for different diagnostic modalities to follow up abnormal colorectal cancer screening results: a hypothetical vignette study.

Authors:  Aradhna Kaushal; Sandro Tiziano Stoffel; Robert Kerrison; Christian von Wagner
Journal:  BMJ Open       Date:  2020-07-26       Impact factor: 2.692

6.  Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality.

Authors:  Luigi Ricciardiello; Clarissa Ferrari; Michela Cameletti; Federica Gaianill; Francesco Buttitta; Franco Bazzoli; Gian Luigi de'Angelis; Alberto Malesci; Luigi Laghi
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-06       Impact factor: 11.382

7.  Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies.

Authors:  Mathias M Petersen; Linnea Ferm; Jakob Kleif; Thomas B Piper; Eva Rømer; Ib J Christensen; Hans J Nielsen
Journal:  Cancers (Basel)       Date:  2020-09-12       Impact factor: 6.639

8.  Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.

Authors:  Manuel Zorzi; Jessica Battagello; Kevin Selby; Giulia Capodaglio; Susanna Baracco; Silvia Rizzato; Enrico Chinellato; Stefano Guzzinati; Massimo Rugge
Journal:  Gut       Date:  2021-03-31       Impact factor: 23.059

9.  Impact of COVID-19 pandemic on fecal immunochemical test screening uptake and compliance to diagnostic colonoscopy.

Authors:  Shao-Yi Cheng; Chu-Fen Chen; Hsien-Chin He; Li-Chun Chang; Wen-Feng Hsu; Ming-Shiang Wu; Han-Mo Chiu
Journal:  J Gastroenterol Hepatol       Date:  2020-12-02       Impact factor: 4.369

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.